Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study

Raia-Barjat, Tiphaïne; Prieux, Carole; Gris, Jean‐Christophe; Chapelle, Céline; Laporte, Silvy; Chauleur, Céline

doi:10.1080/14767058.2017.1378325

Cited by 20 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previous research (3,16,28,32,36,37) we showed that PlGF concentrations were positively associated to birth weight Z-score, while sFlt-1 concentrations and the sFlt-1/PlGF-ratio were negatively associated to the same outcome. The strongest correlation between angiogenic markers and birth weight were seen in women with preeclampsia or preterm delivery.…”

Section: Discussionsupporting

confidence: 93%

Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study

Thorsen

Andersen

Birukov

et al. 2018

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study

Thorsen

Andersen

Birukov

et al. 2018

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

show abstract

“…However, more important is the possibility of the drug preventing low birth weight in women at high risk for developing FGR. This potential may be forthcoming, considering that it is possible to determine the probability of developing FGR based on the levels of angiogenic factors in maternal blood [33]. We are still waiting the final results of the STRIDER multicenter trials that are researching sildenafil therapy for early-onset intrauterine growth restriction pregnancies [34].…”

Section: Discussionmentioning

confidence: 99%

“…The second option seems more plausible pathophysiologically. Therefore, it is necessary to identify the risk group for preeclampsia and/or fetal growth restriction, a condition that is fortunately possible, based on the levels of angiogenic factors in maternal blood and uterine Doppler flow [37]. Besides that, Brownfoot et al reported that sildenafil is associated with a reduction in circulating sFlt-1 levels in a patient with preterm preeclampsia [38].…”

Section: Discussionmentioning

confidence: 99%

The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Background The number of studies associating the use of sildenafil in gestation is increasing. This drug inhibits phosphodiesterase type 5 (PDE5), an enzyme responsible for degradation of nitric oxide, and its efficacy is greater in the placental territory, as the maternal side of the placenta have more PDE5 than other sites. For this reason, promising results have been observed related to the prevention of preeclampsia and intrauterine growth restriction and to improvement of maternal-fetal morbidity in cases of placental insufficiency. Objective To evaluate the benefits of using sildenafil in pregnancy. Searched strategy MEDLINE, ClinicalTrials.gov, Embase, LILACS and Cochrane databases were searched through September 2018. There was no restriction in language or year of publication. This study was registered in PROSPERO (CRD42017060288). Selection criteria Randomized clinical trials which used sildenafil for treatment or prevention of obstetric diseases compared with placebo were selected. Data collection and analysis The results were obtained using the inverse variance method for continuous variables and Man-Whitney for categorical variables. Main results Among a population of 598 pregnant women from the seven clinical trials included, 139 had pre-eclampsia, 275 had intrauterine growth restriction, and 184 had oligohydramnios. A significant increase of 222.58 grams [27.75 to 417.41] was observed in the fetal weight at birth of patients taking sildenafil. The other outcomes did not show any statistical significance. This may be due to the small number of patients used in each study and the great heterogeneity between the groups. Conclusions Sildenafil could be associated with increasing fetal weight at birth in placental insufficiency despite the limitations of this meta-analysis, even though more studies in this field are needed to introduce this drug into obstetric clinical practice.

show abstract

“…While several candidate predictive markers have been identified in recent years, such as sFLT-1 and soluble endoglin, there are no current means for accurately predicting the risk of severe preeclampsia or the likelihood of preterm delivery in affected cases. 1,[37][38][39] Recent data also suggest that changes in specific haemostatic markers (including coagulation, fibrinolytic and platelet parameters) may be associated with EOP and severe disease, although the predictive values of these observations have also yet to be determined. [40][41][42] The lack of an effective predictive model, along with the lack of effective therapies, poses major challenges for clinicians engaged in the management of this disease and the significant associated burden of morbidity and mortality.…”

Section: Introduction Preeclampsia: Pathogenesis Clinical Features Amentioning

confidence: 99%

Pathophysiology of the Venous Thromboembolism Risk in Preeclampsia

et al. 2020

View full text Add to dashboard Cite

SummaryHaemostatic derangements are a hallmark of preeclampsia and appear to favour an increased risk of venous thromboembolism. However, haemorrhagic complications have also been reported. The mechanisms underlying these competing risks remain to be fully elucidated although recent work has highlighted the role of placental factors, such as extra-cellular vesicles and inflammatory mediators, in modulating these haemostatic derangements as well as driving progression of preeclampsia. Identifying affected women at risk of thrombosis and managing the competing thrombotic and haemorrhagic risks continue to be a significant clinical challenge. Derangements in blood coagulation are also implicated in the pathogenesis of preeclampsia; however, the role of antiplatelet or anticoagulant drugs in the management of this disorder remains a source of debate. Further characterisation of the underlying molecular mechanisms would likely be of major translational relevance and could provide insights into the pathogenesis of this disease as well as the associated haemostatic dysfunction.

show abstract

Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study

Abstract: In high-risk women, angiogenic factors are disturbed before the onset of preeclampsia and this is true for intrauterine growth restriction.

Cited by 20 publications

References 25 publications

Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study

Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study

The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis

Pathophysiology of the Venous Thromboembolism Risk in Preeclampsia

Contact Info

Product

Resources

About